Blanka Rybka

Blanka Rybka

Auto-generated profile, based on publicly available information

Blanka Rybka

Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
IBI. Bil-Lula
I. Bil-Lula
Marek UssowiczMarek Ussowicz
Marek Ussowicz
BRB. Rybka
B. Rybka
DWD. Wendycz-Domalewska
D. Wendycz-Domalewska
RRR. Ryczan
R. Ryczan
MWM. Woźniak
M. Woźniak

25 October 2016 in Central European Journal of Immunology
Verified
Journal Article
Open access
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
MMMonika Mielcarek
Monika Mielcarek
BRBlanka Rybka
Blanka Rybka
RRRenata Ryczan-Krawczyk
Renata Ryczan-Krawczyk
DNDorota Noworolska-Sauren
Dorota Noworolska-Sauren
KKKrzysztof Kałwak
Krzysztof Kałwak
Immune reconstitution was studied prospectively in 86 children who underwent allogeneic haematopoietic stem cell transplantation (HSCT). We analysed the risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation in correlation with the kinetics of immune recovery and in relation to other potential risk factors that may influence the reactivation of these viruses including: diagnosis, type of HSCT, source of stem cells, type of conditioning, or the occurrence of graft-versus-host disease (GvHD). The absolute number of lymphocyte subpopulations in peripheral blood was evaluated in seven timepoints following HSCT. Significantly lower values of both CD3+ and CD3+CD8+ lymphocytes on day +14 and significantly higher values of both these subsets on day +168 post-transplant in patients with CMV reactivation were observed. Significantly lower values of CD3+CD4+ subpopulation were noted in patients with CMV reactivation on day +28 post allo-HSCT. Significantly lower lymphocyte values in the group with EBV reactivation comparing with the group without EBV reactivation were confirmed only in the case of pan-B lymphocytes (CD19+) subpopulation on day +21, +28, and +84 post allo-HSCT. We identified the impact of CMV reactivation on occurrence of the intestinal acute GvHD, which occurred more frequently in the group with CMV reactivation compared with patients without reactivation. Higher incidence of chronic GvHD was also observed in patients with CMV reactivation compared to the group without reactivation. EBV reactivation occurred more frequently in patients receiving transplants from matched unrelated donors, in particular after peripheral blood stem cell transplantation and while implementing antithymocyte globulin as GvHD prophylaxis.

17 September 2010 in Archives of Virology
Verified
Journal Article
Open access
PDF file
IBIwona Bil-Lula
Iwona Bil-Lula
Marek UssowiczMarek Ussowicz
Marek Ussowicz
BRBlanka Rybka
Blanka Rybka
DWDanuta Wendycz-Domalewska
Danuta Wendycz-Domalewska
RRRenata Ryczan
Renata Ryczan
MWMieczysław Woźniak
Mieczysław Woźniak
After stem cell transplantation, human patients are prone to life-threatening opportunistic infections with a plethora of microorganisms. We report a retrospective study on 116 patients (98 children, 18 adults) who were transplanted in a pediatric bone marrow transplantation unit. Blood, urine and stool samples were collected and monitored for adenovirus (AdV) DNA using polymerase chain reaction (PCR) and real-time PCR (RT-PCR) on a regular basis. AdV DNA was detected in 52 (44.8%) patients, with mortality reaching 19% in this subgroup. Variables associated with adenovirus infection were transplantations from matched unrelated donors and older age of the recipient. An increased seasonal occurrence of adenoviral infections was observed in autumn and winter. Analysis of immune reconstitution showed a higher incidence of AdV infections during periods of low T-lymphocyte count. This study also showed a strong interaction between co-infections of AdV and BK polyomavirus in patients undergoing hematopoietic stem cell transplantations.

1 November 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
Marek UssowiczMarek Ussowicz
Marek Ussowicz
EWElżbieta Wawrzyniak-Dzierżek
Elżbieta Wawrzyniak-Dzierżek
MMMonika Mielcarek-Siedziuk
Monika Mielcarek-Siedziuk
MSMałgorzata Salamonowicz
Małgorzata Salamonowicz
JFJowita Frączkiewicz
Jowita Frączkiewicz
KKKrzysztof Kałwak
Krzysztof Kałwak
Ataxia-telangiectasia (A-T) syndrome is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ataxia-telangiectasia mutated gene manifested by progressive neurodegeneration, telangiectasias of sclera and skin, immune deficiency with sinopulmonary infections, and increased incidence of lymphoid malignancies and solid tumors. Three children with A-T underwent allogeneic stem cell transplantation (SCT) using protocols for Fanconi anemia. All 3 patients were engrafted with a mixed donor-recipient chimerism, but the full donor engraftment was observed in the T lymphocyte compartment. Immunologic recovery resulted in T cell production and lack of symptomatic infections. Regular intravenous immunoglobulin supplementation was needed until IgG production recovered, which depended on pretransplant serotherapy. During the observation period patients did not require hospital admission, and none of the transplanted patients developed sinopulmonary infections. Neurologic functions in reported patients were impaired and slowly deteriorated after transplantation, but no immediate toxicities were observed. The following hallmark features of A-T were present after SCT: neurologic symptoms, growth failure, telangiectasia formation, or increased serum alpha fetoprotein. SCT can help control immune deficiency constituting 1 of the features of A-T, and elimination of autologous hematopoiesis reduces the risk of lymphoid malignancies. Resolving crucial problems with qualification for SCT depends on balancing the risk and benefits of transplant therapy.

17 November 2003 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
EGE Gorczyñska
E Gorczyñska
DTD Turkiewicz
D Turkiewicz
JTJ Toporski
J Toporski
KKK Kalwak
K Kalwak
BRB Rybka
B Rybka
ACA Chybicka
A Chybicka

24 June 2003 in Leukemia Research
Verified
Journal Article
Closed access
DTDominik Turkiewicz
Dominik Turkiewicz
EGEwa Gorczynska
Ewa Gorczynska
JTJacek Toporski
Jacek Toporski
KKKrzysztof Kalwak
Krzysztof Kalwak
BRBlanka Rybka
Blanka Rybka
ACAlicja Chybicka
Alicja Chybicka